» Articles » PMID: 34172897

Mucolipidosis Type II and Type III: a Systematic Review of 843 Published Cases

Overview
Journal Genet Med
Publisher Elsevier
Specialty Genetics
Date 2021 Jun 26
PMID 34172897
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Mucolipidosis (ML) II, MLIII alpha/beta, and MLIII gamma are rare autosomal recessive lysosomal storage disorders. Data on the natural course of the diseases are scarce. These data are important for counseling, therapies development, and improvement of outcome. The aim of this study is to gain knowledge on the natural history of ML by obtaining data on survival, symptom onset, presenting symptoms, diagnosis, and pathogenic variants associated with the MLII or MLIII phenotype.

Methods: A systematic review on all published MLII and MLIII cases between 1968 and August 2019 was performed.

Results: Three hundred one articles provided data on 843 patients. Median age at diagnosis: 0.7 for MLII and 9.0 years for MLIII. Median survival: 5.0 for MLII and 62.0 years for MLIIIII. Median age of death: 1.8 for MLII and 33.0 years for MLIII. Most frequent causes of death in all ML were pulmonary and/or cardiac complications. Pathogenic variants were described in 388 patients (GNPTAB: 571, GNPTG 179).

Conclusion: This review provides unique insights into the natural history of MLII and MLIII, with a clear genotype-phenotype correlation with the most frequent pathogenic variant c.3503_3504del in MLII and in MLIII alpha/beta c.22A>G for GNPTAB. All pathogenic GNPTG variants resulted in MLIII gamma.

Citing Articles

Clinical and molecular characteristics of 20 Chinese probands with Mucolipidosis type II and III alpha/beta.

Feng Y, Huang Y, Zhao X, Sheng H, Su X, Yin X BMC Pediatr. 2024; 24(1):830.

PMID: 39710647 PMC: 11665131. DOI: 10.1186/s12887-024-05223-x.


The mucolipidosis III-causing mutation in c.1760G>C, disrupts the development of somites in rats.

Nong T, Li J, Li X, Li Y, Li Z, Shi W Genes Dis. 2024; 11(6):101172.

PMID: 39157455 PMC: 11327505. DOI: 10.1016/j.gendis.2023.101172.


Identification of novel therapeutic targets for chronic kidney disease and kidney function by integrating multi-omics proteome with transcriptome.

Si S, Liu H, Xu L, Zhan S Genome Med. 2024; 16(1):84.

PMID: 38898508 PMC: 11186236. DOI: 10.1186/s13073-024-01356-x.


[Importance of lysosomal storage diseases in rheumatology].

Aries C, Rudolph C, Muschol N Z Rheumatol. 2024; 83(5):393-400.

PMID: 38802503 DOI: 10.1007/s00393-024-01521-y.


Unraveling mucolipidosis type III gamma through whole genome sequencing in late-onset retinitis pigmentosa: a case report.

De Geer K, Mascianica K, Naess K, Sardh E, Lindstrand A, Bjorck E BMC Ophthalmol. 2023; 23(1):394.

PMID: 37752499 PMC: 10523780. DOI: 10.1186/s12886-023-03136-4.


References
1.
Maroteaux P, Lamy M . [Hurler's pseudo-polydystrophy]. Presse Med (1893). 1966; 74(55):2889-92. View

2.
Velho R, Harms F, Danyukova T, Ludwig N, Friez M, Cathey S . The lysosomal storage disorders mucolipidosis type II, type III alpha/beta, and type III gamma: Update on GNPTAB and GNPTG mutations. Hum Mutat. 2019; 40(7):842-864. DOI: 10.1002/humu.23748. View

3.
Tabone L, Caillaud C, Amaddeo A, Khirani S, Michot C, Couloigner V . Sleep-disordered breathing in children with mucolipidosis. Am J Med Genet A. 2019; 179(7):1196-1204. DOI: 10.1002/ajmg.a.61167. View